scholarly journals Identification of a prognostic long non-coding RNA signature in breast cancer

2020 ◽  
Author(s):  
Gaochen Lan ◽  
Xiaoling Yu ◽  
Yanna Zhao ◽  
Jinjian Lan ◽  
Wan Li ◽  
...  

Abstract Background: Breast cancer is the most common malignant disease among women. At present, more and more attention has been paid to long non-coding RNAs (lncRNAs) in the field of breast cancer research. We aimed to investigate the expression profiles of lncRNAs and construct a prognostic lncRNA for predicting the overall survival (OS) of breast cancer.Methods: The expression profiles of lncRNAs and clinical data with breast cancer were obtained from The Cancer Genome Atlas (TCGA). Differentially expressed lncRNAs were screened out by R package (limma). The survival probability was estimated by the Kaplan‑Meier Test. The Cox Regression Model was performed for univariate and multivariate analysis. The risk score (RS) was established on the basis of the lncRNAs’ expression level (exp) multiplied regression coefficient (β) from the multivariate cox regression analysis with the following formula: RS=exp a1 * β a1 + exp a2 * β a2 +……+ exp an * β an. Functional enrichment analysis was performed by Metascape.Results: A total of 3404 differentially expressed lncRNAs were identified. Among them, CYTOR, MIR4458HG and MAPT-AS1 were significantly associated with the survival of breast cancer. Finally, The RS could predict OS of breast cancer (RS=exp CYTOR * β CYTOR + exp MIR4458HG * β MIR4458HG + exp MAPT-AS1 * β MAPT-AS1). Moreover, it was confirmed that the three-lncRNA signature could be an independent prognostic biomarker for breast cancer (HR=3.040, P=0.000).Conclusions: This study established a three-lncRNA signature, which might be a novel prognostic biomarker for breast cancer.

2020 ◽  
Author(s):  
Gaochen Lan ◽  
Xiaoling Yu ◽  
Yanna Zhao ◽  
Jinjian Lan ◽  
Wan Li ◽  
...  

Abstract Background: Breast cancer is the most common malignant disease among women. At present, more and more attention has been paid to long non-coding RNAs (lncRNAs) in the field of breast cancer research. We aimed to investigate the expression profiles of lncRNAs and construct a prognostic lncRNA for predicting the overall survival (OS) of breast cancer. Methods: The expression profiles of lncRNAs and clinical data with breast cancer were obtained from The Cancer Genome Atlas (TCGA). Differentially expressed lncRNAs were screened out by R package (limma). The survival probability was estimated by the Kaplan‑Meier Test. The Cox Regression Model was performed for univariate and multivariate analysis. The risk score (RS) was established on the basis of the lncRNAs’ expression level (exp) multiplied regression coefficient (β) from the multivariate cox regression analysis with the following formula: RS=exp a1 * β a1 + exp a2 * β a2 +……+ exp an * β an . Functional enrichment analysis was performed by Metascape. Results: A total of 3404 differentially expressed lncRNAs were identified. Among them, CYTOR , MIR4458HG and MAPT-AS1 were significantly associated with the survival of breast cancer. Finally, The RS could predict OS of breast cancer (RS=exp CYTOR * β CYTOR + exp MIR4458HG * β MIR4458HG + exp MAPT-AS1 * β MAPT-AS1 ). Moreover, it was confirmed that the three-lncRNA signature could be an independent prognostic biomarker for breast cancer (HR=3.040, P=0.000). Conclusions: This study established a three-lncRNA signature, which might be a novel prognostic biomarker for breast cancer.


2020 ◽  
Author(s):  
Yang Wang ◽  
Chengping Hu

Abstract Background: Long non-coding RNAs (lncRNAs) have been reported to play essential roles in tumorigenesis and cancers prognosis, and they can be a potential cancer prognostic markers. However, in lung adenocarcinoma(LUAD), how lncRNA signatures predict the survival of patients is poorly understood. Our study aims to explore lncRNA signatures and prognostic function in LUAD.Methods: The expression and prognosis data of lncRNAs in LUAD patients was collected from the Cancer Genome Atlas (TCGA) data. All analyses were performed using the R package (version 3.6.2). Metascape, STRING and Cytoscape were used for enrichment analysis and function prediction of the lncRNA co-expressed protein-coding genes.Results: We have collected lncRNA expression data in 466 LUAD tumors, and a six-lncRNA signature(RP11-79H23.3, RP11-309M7.1, CTD-2357A8.3, RP11-108P20.4, U47924.29, LHFPL3-AS2) has been shown to be significantly related to LUAD patients’ overall survival. According to the lncRNA signatures, the high-risk and low-risk groups were divided in LUAD patients with different survival rates. Further multivariable cox regression analysis showed that the prognostic value of this signature was independent of clinical factors. The potential functional roles and hub co-expressed protein-coding genes in the six prognostic lncRNAs are shown in the functional enrichment analysis.Conclusions: These results showed that these six lncRNAs could be independent predicted prognostic biomarkers in LUAD patients.


2021 ◽  
Author(s):  
Xiaoyu Ji ◽  
Guangdi Chu ◽  
Jinwen Jiao ◽  
Teng Lv ◽  
Yulong Chen ◽  
...  

Abstract Objective: Cervical cancer (CC) is one of the most common types of malignant female cancer, and its incidence and mortality are not optimistic. Protein panels can be a powerful prognostic factor for many types of cancer. The purpose of our study was to investigate a proteomic panel to predict survival of patients with common CC. Methods and results: The protein expression and clinicopathological data of CC were downloaded from The Cancer Proteome Atlas (TCPA) and The Cancer Genome Atlas (TCGA) database, respectively. We selected the prognosis-related proteins (PRPs) by univariate Cox regression analysis and found that the results of functional enrichment analysis were mainly related to apoptosis. We used Kaplan–Meier(K-M) analysis and multivariable Cox regression analysis further to screen PRPs to establish a prognostic model, including BCL2, SMAD3, and 4EBP1-pT70. The signature was verified to be independent predictors of OS by Cox regression analysis and the Area Under Curves. Nomogram and subgroup classification were established based on the signature to verify its clinical application. Furthermore, we looked for the co-expressed proteins of three-protein panel as potential prognostic proteins.Conclusion: A proteomic signature independently predicted OS of CC patients, and the predictive ability was better than the clinicopathological characteristics. This signature can help improve prediction for clinical outcome and provides new targets for CC treatment.


2020 ◽  
Author(s):  
Pinping Jiang ◽  
Wei Sun ◽  
Ningmei Shen ◽  
Qiang Wang ◽  
Shouyu Wang ◽  
...  

Abstract Background Autophagy, as a lysosomal degradation pathway, has been reported to be involved in various pathologies, including cancer. However, the expression profiles of autophagy-related genes (ARGs) in endometrial cancer (EC) remain poorly understood. Methods In this study, we analyzed the expression of MRGs using The Cancer Genome Atlas (TCGA) data to screen differentially expressed MRGs (DE-MRGs) significantly correlated to EC patients’ prognosis. Gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis of DE-MRGs were investigated. LASSO algorithm and Cox regression analysis were performed to select MRGs closely related to EC patients’ outcomes. A prognostic signature was developed and the efficacy were validated in part of and the entire TCGA EC cohort. Moreover, we developed a comprehensive nomogram including the risk model and clinical features to predict EC patients' survival probability. Results Ninety-four ARGs significantly dysregulated in EC samples compared with the normal control samples. Functional enrichment analysis showed these differentially expressed ARGs (DE-ARGs) were highly enriched in apoptosis, P53 signaling pathway, and various cancer development. Among the 94 DE-ARGs, we subsequently screen out four-ARGs closely related to EC patients outcomes, which are ERBB2, PTEN, TP73 and ARSA. Based on the expression and coefficiency of 4 DE-ARGs, we developed a prognostic signature and further validated its efficacy in part of and the entire TCGA EC cohort. The four ARGs signature was independent of other clinical features, and was proved to effectively distinguish high- or low-risk EC patients and predicted patients' OS accurately. Moreover, the nomogram showed the excellent consistency between the prediction and actual observation in terms of patients' 3- and 5-year survival rates. Conclusions It was suggested that the ARG prognostic model and the comprehensive nomogram may guide the precise outcome prediction and rational therapy in clinical practice.


2020 ◽  
Author(s):  
Pinping Jiang ◽  
Wei Sun ◽  
Ningmei Shen ◽  
Xiaohao Huang ◽  
Shilong Fu

Abstract Background: Metabolic abnormalities have recently been widely studied in various cancer types. This study aims to explore the expression profiles of metabolism-related genes (MRGs) in endometrial cancer (EC). Methods: We analyzed the expression of MRGs using The Cancer Genome Atlas (TCGA) data to screen differentially expressed MRGs (DE-MRGs) significantly correlated to EC patients’ prognosis. Functional pathway enrichment analysis of DE-MRGs were investigated. LASSO algorithm and Cox regression analysis were performed to select MRGs closely related to EC patients’ outcomes. A prognostic signature was developed and the efficacy were validated in part of and the entire TCGA EC cohort. Moreover, we developed a comprehensive nomogram including the risk model and clinical features to predict EC patients' survival probability.Results: Forty-seven differentially expressed MRGs (DE-MRGs) were significantly correlate to EC patients’ prognosis. Functional enrichment analysis showed these MRGs were highly enriched in amino acid, glycolysis, and glycerophospholipid metabolism. Nine MRGs were screened out to closely relate to EC patients’ outcomes, which are CYP4F3, CEL, GPAT3, LYPLA2, HNMT, PHGDH, CKM, UCK2 and ACACB. Based on nine DE-MRGs, we developed a prognostic signature and its efficacy in part of and the entire TCGA EC cohort was validated. The nine-MRGs signature was independent of other clinical features, and could effectively distinguish high- or low-risk EC patients and predicted patients' OS. The nomogram showed excellent consistency between prediction and actual survival observation. Conclusions: The MRG prognostic model and the comprehensive nomogram could guide for precise outcom predicting and rational therapy in clinical practice.


2021 ◽  
Vol 2021 ◽  
pp. 1-13
Author(s):  
Peng Qin ◽  
Mengyu Zhang ◽  
Xue Liu ◽  
Ziming Dong

Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related death. HBV infection is an important risk factor for the tumorigenesis of HCC, given that the inflammatory environment is closely related to morbidity and prognosis. Consequently, it is of urgent importance to explore the immunogenomic landscape to supplement the prognosis of HCC. The expression profiles of immune‐related genes (IRGs) were integrated with 377 HCC patients to generate differentially expressed IRGs based on the Cancer Genome Atlas (TCGA) dataset. These IRGs were evaluated and assessed in terms of their diagnostic and prognostic values. A total of 32 differentially expressed immune‐related genes resulted as significantly correlated with the overall survival of HCC patients. The Gene Ontology functional enrichment analysis revealed that these genes were actively involved in cytokine‐cytokine receptor interaction. A prognostic signature based on IRGs (HSPA4, PSME3, PSMD14, FABP6, ISG20L2, TRAF3, NDRG1, NRAS, CSPG5, and IL17D) stratified patients into high-risk versus low-risk groups in terms of overall survival and remained as an independent prognostic factor in multivariate analyses after adjusting for clinical and pathologic factors. Several IRGs (HSPA4, PSME3, PSMD14, FABP6, ISG20L2, TRAF3, NDRG1, NRAS, CSPG5, and IL17D) of clinical significance were screened in the present study, revealing that the proposed clinical-immune signature is a promising risk score for predicting the prognosis of HCC.


2020 ◽  
Author(s):  
Buwei Teng ◽  
Yuhan Yang ◽  
Zengya Guo ◽  
Kundong Zhang ◽  
Xiaofeng Wang ◽  
...  

Abstract Background:Pancreatic cancer (PC) is one of the most common cancers,which has poor prognosis.At present, abundant genetic PC samples can be obtained from The Cancer Genome Atlas (TCGA) database to finish comprehensive and reliable immunogenomic analysis. Thus, there is an urgent need to systematically explore the immunogenome of PC to obtain good prognosis.Methods: In this study, according to TCGA and The Genotype-Tissue Expression (GTEx) databases, we investigated the different compositions of leukocytes between PC and normal pancreas tissues, and analyzed the expressions of immune-related genes (IRGs) and the overall survival (OS) of 178 PC patients. Subsequently, computational difference algorithm and COX regression analyses were employed to assess the differentially expressed and OS-related IRGs in PC patients. Moreover, the underlying action mechanisms and properties of these IRGs were investigated by using computational biology. Finally, multivariable COX analysis was used to develop a novel prognostic biomarker for PC according to these IRGs.Results:The results showed that CD4+ memory T cells and M0 macrophages were more common and highly dominated in PC tissues relative to the non-tumor tissues. Functional enrichment analysis demonstrated that the differentially expressed and OS‐related IRGs were actively involved in the PI3K-Akt signaling pathway. A prognostic signature according to these differentially expressed IRGs (CD2AP, IL20RB, MYEOV, NUSAP1, PCDH1, RAB27B, TNFSF10, TOP2A, TPX2, TYK2, WNT7A and BUB1B) was moderately used for prognostic predictions. Further study indicated that RAB27B was negatively related to CD4 T cells while TYK2 was positively correlated with CD4 T cells. Conclusions: Taken together, this study screened several significant IRGs, demonstrated the drivers of immune repertoire, and indicated the importance of these PC-specific IRGs in the prognosis of PC.


2020 ◽  
Author(s):  
Pinping Jiang ◽  
Wei Sun ◽  
Ningmei Shen ◽  
Qiang Wang ◽  
Shouyu Wang ◽  
...  

Abstract Background Autophagy, as a lysosomal degradation pathway, has been reported to be involved in various pathologies, including cancer. However, the expression profiles of autophagy-related genes (ARGs) in endometrial cancer (EC) remain poorly understood. Methods In this study, we analyzed the expression of MRGs using The Cancer Genome Atlas (TCGA) data to screen differentially expressed MRGs (DE-MRGs) significantly correlated to EC patients’ prognosis. Gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis of DE-MRGs were investigated. LASSO algorithm and Cox regression analysis were performed to select MRGs closely related to EC patients’ outcomes. A prognostic signature was developed and the efficacy were validated in part of and the entire TCGA EC cohort. Moreover, we developed a comprehensive nomogram including the risk model and clinical features to predict EC patients' survival probability. Results Ninety-four ARGs significantly dysregulated in EC samples compared with the normal control samples. Functional enrichment analysis showed these differentially expressed ARGs (DE-ARGs) were highly enriched in apoptosis, P53 signaling pathway, and various cancer development. Among the 94 DE-ARGs, we subsequently screen out four-ARGs closely related to EC patients outcomes, which are ERBB2, PTEN, TP73 and ARSA. Based on the expression and coefficiency of 4 DE-ARGs, we developed a prognostic signature and further validated its efficacy in part of and the entire TCGA EC cohort. The four ARGs signature was independent of other clinical features, and was proved to effectively distinguish high- or low-risk EC patients and predicted patients' OS accurately. Moreover, the nomogram showed the excellent consistency between the prediction and actual observation in terms of patients' 3- and 5-year survival rates. Conclusions It was suggested that the ARG prognostic model and the comprehensive nomogram may guide the precise outcome prediction and rational therapy in clinical practice.


2021 ◽  
Author(s):  
GenYi Qu ◽  
Guang Yang ◽  
Yong Xu ◽  
Maolin Xiang ◽  
Cheng Tang

Abstract Background: Bladder cancer (BLCA) is one of the most common urinary tract malignant tumors. It is associated with poor outcomes, and its etiology and pathogenesis are not fully understood. There is great hope for immunotherapy in treating many malignant tumors; therefore, it is worthwhile to explore the use of immunotherapy for BLCA.Methods: Gene expression profiles and clinical information were obtained from The Cancer Genome Atlas (TCGA), and immune-related genes (IRGs) were downloaded from the Immunology Database and Analysis Portal. Differentially-expressed and survival-associated IRGs in patients with BLCA were identified using computational algorithms and Cox regression analysis. We also performed functional enrichment analysis. Based on IRGs, we employed multivariate Cox analysis to develop a new prognostic index.Results: We identified 261 IRGs that were differentially expressed between BLCA tissue and adjacent tissue, 30 of which were significantly associated with the overall survival (all P<0.01). According to multivariate Cox analysis, nine survival-related IRGs (MMP9, PDGFRA, AHNAK, OAS1, OLR1, RAC3, IGF1, PGF, and SH3BP2) were high-risk genes. We developed a prognostic index based on these IRGs and found it accurately predicted BLCA outcomes associated with the TNM stage. Intriguingly, the IRG-based prognostic index reflected infiltration of macrophages.Conclusions: An independent IRG-based prognostic index provides a practical approach for assessing patients' immune status and prognosis with BLCA. This index independently predicted outcomes of BLCA.


2020 ◽  
Vol 2020 ◽  
pp. 1-8
Author(s):  
Yuntao Shi ◽  
Yingying Zhuang ◽  
Jialing Zhang ◽  
Mengxue Chen ◽  
Shangnong Wu

Objective. Although noncoding RNAs, especially the microRNAs, have been found to play key roles in CRC development in intestinal tissue, the specific mechanism of these microRNAs has not been fully understood. Methods. GEO and TCGA database were used to explore the microRNA expression profiles of normal mucosa, adenoma, and carcinoma. And the differential expression genes were selected. Computationally, we built the SVM model and multivariable Cox regression model to evaluate the performance of tumorigenic microRNAs in discriminating the adenomas from normal tissues and risk prediction. Results. In this study, we identified 20 miRNA biomarkers dysregulated in the colon adenomas. The functional enrichment analysis showed that MAPK activity and MAPK cascade were highly enriched by these tumorigenic microRNAs. We also investigated the target genes of the tumorigenic microRNAs. Eleven genes, including PIGF, TPI1, KLF4, RARS, PCBP2, EIF5A, HK2, RAVER2, HMGN1, MAPK6, and NDUFA2, were identified to be frequently targeted by the tumorigenic microRNAs. The high AUC value and distinct overall survival rates between the two risk groups suggested that these tumorigenic microRNAs had the potential of diagnostic and prognostic value in CRC. Conclusions. The present study revealed possible mechanisms and pathways that may contribute to tumorigenesis of CRC, which could not only be used as CRC early detection biomarkers, but also be useful for tumorigenesis mechanism studies.


Sign in / Sign up

Export Citation Format

Share Document